uniQure Hopeful In Accelerated Approval Potential For Huntington’s Disease

The biotech announced updated interim Phase I/II data for its gene therapy AMT-130, showing statistically significant improvement compared with an external control.

Updated interim data from uniQure N.V.’s Phase I/II study of its gene therapy AMT-130 in Huntington’s disease showed slowing of decline among treated patients compared with an external control, raising the company’s optimism that it may have a pathway to accelerated approval from the US Food and Drug Administration.

The data released 9 July show that patients receiving the high dose of AMT-130 had an 80% slowing of disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bluebird Builds Out Leadership Team Under Private Equity Ownership

02 Jul 2025

• By Jessica Merrill

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

24 Jun 2025

• By Alaric DeArment

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

24 Jun 2025

• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Syncona Looks To Go Private As Market Decline Deepens

19 Jun 2025

• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

24 Jun 2025

• By Alaric DeArment

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.